Effect of genetic alterations of cytarabine-metabolizing enzymes in childhood acute lymphoblastic leukemia

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 3, 2010, Pages 103-108

  Banklaui, Chumphorn ^a   Jindadamrongwech, Sumalee ^a   Sawangpanich, Ruchchadol ^a   Apibal, Suntaree ^a   Hongeng, Suradej ^a   Paisooksantivatana, Karan ^a   Pakakasama, Samart ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG METABOLIZING ENZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLELE; ANEMIA; ARTICLE; CANCER STAGING; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; DIARRHEA; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MUTATION; NEUTROPENIA; REPEATED DRUG DOSE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA;

EID: 79551637167     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.103     Document Type: Article

References (18)

1. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ; Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005;19:2101-2116.
2. Momparler RL. Kinetic and template studies with 1-b-D-Arabinofuranosylcytosine 5'-triphos-phate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol 1972;8:362-70.
3. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980;255:8997-9000.
4. Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002;41:705-18.
5. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PHM, Schellens JHM. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 2006;62:681-4.
6. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, Maeba H, Ito T, Sasaki T, Koizumi S. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003;13:29-38.
7. Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004;14:759-68.
8. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Wein-shilboum RM. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006;12:1794-803.
9. Capizzi RL, Poole M, Cooper MR, Richards F 2nd, Stuart JJ, Jackson DV Jr, White DR, Spurr CL, Hopkins JO, Muss HB, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood 1984;63:694-700.
10. Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer 2007;49:1070-3.
11. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, Cheng C, Kun LE, Raimondi SC, Behm FG, Downing JR, Relling MV, Evans WE; Total Therapy Study XIIIB at St Jude Children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St Jude children's research hospital. Blood 2004;104:2690-6.
12. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rational an design of total therapy study XV for newly diagnosed child-hood acute lymphoblastic leukemia. Ann Hematol 2004;83:S124-6.
13. Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet 2009;24:553-6.
14. Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Hematol 2008;144:388-94.
15. Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G, Schaich M. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009;23:1929-32.
16. Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Hematol 2008;143:481-9.
17. Motwani J, Jesson J, Sturch E, Jones S, Eyre L, Short P, Davies P, Williams MD, Darbyshire PJ, Hill FG, Lawson S. Predictive value of flow cytometric minimal residual disease analysis in child-hood acute lymphoblastic leukaemia at the end of remission induction therapy-results from a single UK centre. Br J Hematol 2008;144:133-5.
18. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D. Clinical important of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-6.